Price Alert

Vor Biopharma Inc. (VOR)

NASDAQ: VOR · Real-Time Price · USD

1.74

-0.07 (-4.13%)

At close: Sep 12, 2025, 3:59 PM

1.77

1.72%

After-hours: Sep 12, 2025, 07:43 PM EDT

-4.13% (1D)

Bid	1.74
Market Cap	220.43M
Revenue (ttm)	3.69M
Net Income (ttm)	-1.66B
EPS (ttm)	-13.68
PE Ratio (ttm)	-0.13
Forward PE	-6.21
Analyst	Hold

Ask	1.8
Volume	3,380,494
Avg. Volume (20D)	18,813,237
Open	1.80
Previous Close	1.81
Day's Range	1.73 - 1.87
52-Week Range	0.13 - 3.29
Beta	2.06

About VOR

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol VOR

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for VOR stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

1 month ago

+21.69%

Vor Bio shares are trading higher after the compan... Unlock content with Pro Subscription

1 month ago

+21.69%

Vor Biopharma shares are trading higher following the release of its Q2 reported financial results.

News

1 month ago · benzinga.com

Vor Bio Rallies On Strong Data For Autoimmune Drug Candidate

Vor Bio VOR stock is trading higher on Wednesday with a session volume of 10.83 million compared to the average volume of 17.99 million, as per data from Benzinga Pro.

2 months ago · benzinga.com

Vor Biopharma's RemeGen Deal Paves Way For Multi-Billion Dollar Autoimmune Market

H.C. Wainwright upgraded Vor Biopharma Inc. VOR, highlighting the company's “rebirth” following the in-licensing of telitacicept.

2 months ago · zacks.com

Vor Bio Stock Skyrockets 250% in the Past Week: Here's Why

The VOR stock soars in the past week after a licensing deal with RemeGen. The company also appoints a chief executive officer and chairman.